Body Vision Medical, a medical device company specializing in augmented real-time imaging, announced today that it has received clearance from the U.S. Food and Drug Administration to market LungVision, a novel imaging system that enables accurate real-time navigation and lesion localization during bronchoscopic procedures.
LungVision, the first product based on the Body Vision platform, demonstrated outstanding results through multicenter clinical trials in the U.S. Utilizing a sophisticated augmented reality approach, LungVision allows physicians to plan, visualize, and track endobronchial tools and radiolucent lesions in real time. LungVision’s synergistic imaging merges intraoperative fluoroscopy with pre-operative high resolution imaging, such as computed tomography.
“Body Vision developed unique technology that combines the intelligence of navigation with the simplicity of fluoroscopy,” says D. Kyle Hogarth, MD, FCCP Associate Professor of Medicine, Director of Bronchoscopy at the University of Chicago and one of the first LungVision users in North America. “It enables effective localization and enhanced biopsy of lung lesions, upgrading the standard methods used in our daily practice.”
Body Vision CEO Dorian Averbuch added, “We are thrilled to introduce the Body Vision platform to the medical community. We envision that in the near future, the LungVision system will revolutionize the way physicians diagnose and treat peripheral lung lesions.”